Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2014 Aug;36(6):458–463. doi: 10.1097/MPH.0b013e3182a8f58f

Table I.

Details of Protocol Therapy

Drug and Dosage Day
EZN-3042 (dose assigned at study entry) −5, −2, 8, 15, 22, 29
Vincristine 1.5 mg/m2 IV 1, 8, 15, 22
Prednisone 40 mg/m2/day PO 1–29
Pegaspargase 2500 IU/m2 IV 2, 9, 16, 23
Doxorubicin 60 mg/m2 IV 1
Intrathecal cytarabine 0
Intrathecal methotrexate 15 and 36 (CNS negative)
Triple intrathecal chemotherapy 8, 15, 22, 29 (CNS positive)